We screened myoga extracts for inhibitors of human platelet aggregation and human 5-lipoxygenase. We identified a novel labdane type of diterpene, together with three known diterpenes (miogadial and galanals A and B) from the flower buds of myoga. Spectroscopic data indicated the structure of the new compound to be 12(E)-labdene-15,16,(8)17-trial (miogatrial). Miogatrial and miogadial were potent inhibitors of human platelet aggregation and human 5-lipoxygenase (5-LOX). The sesquiterpene, polygodial, also exhibited strong inhibitory activity against human platelet aggregation and 5-LOX. On the other hand, galanals A and B did not have inhibitory activity in either experimental system. It thus appears that a 3-formyl-3-butenal structure was essential for the potent inhibition of human platelet aggregation and human 5-LOX.
Myoga (Zingiber mioga Roscoe; Zingiberaceae family) is a perennial herb indigenous to eastern Asia and widely cultivated throughout Japan. It has a stalk that extends up to 1 m, with slender leaves reaching 30 cm in length. The flower buds are produced at ground level from underground rhizomes, and they grow to 7-10 cm in length with a pine cone-like shape and are edible during the summer or autumn. Due to their distinctive and pungent flavor, the flower buds are used as a spice and pickled vegetable. The characteristic flavor of the flower buds has been reported to be due to 2-alkyl-3-methoxypyrazine (alkyl = isobutyl, isopropyl) and 8-17-epoxy-12E-labdene-15,16-dial (miogadial 2).
1,2) Of these compounds, we have previously found 2 to be the dominant contributor to the hot taste of the flower buds. 2) In addition, the leaves of the myoga plant are used to wrap and preserve ''manjyu,'' a bun filled with sweetened bean paste. Previous examination of the antimicrobial activities of the constituents of myoga against several strains of bacteria, yeast, and mold indicated that miogadial had potent activity against yeasts and Gram-positive bacteria. 3) A number of investigations have recently been focused on the health benefits of dietary ingredients; for example, in combatting cancer, atherosclerosis, and diabetes. Under pathophysiological conditions, platelet activation may result in peripheral, cardiovascular, or cerebrovascular thrombosis, with serious consequences. 4) Aspirin has been used for anti-platelet therapy for several decades, but it can promote the formation of gastric ulcers and induce gastrointestinal bleeding. 4) The natural products of the Zingiberaceae family, such as ginger, have therefore been studied by many investigators as a source of new anti-platelet agents. [5] [6] [7] [8] [9] [10] [11] [12] [13] Although the flower buds and rhizomes of myoga have been used since ancient times in Japan and China as a herbal medicine against cough and rheumatism, 14, 15) y To whom correspondence should be addressed. Fax: +81-27-352-1169; E-mail: mabe@takasaki-u.ac.jp there have been only a few studies on its physiological effects. Iwashita et al. 16) have reported that a myoga extract significantly reduced the glycerol-3-phosphate dehydrogenase activity and triglyceride accumulation in 3T3-L1 cells and prevented the increase in body weight and epididymal fat weight of male ICR mice. In addition, Miyoshi et al. 17) have reported that galanals A 3 and B 4 isolated from the flower buds of myoga had potent cytotoxic activity in Jurkat human T lymphoma cells due to the induction of apoptosis. Most recently, Kim et al. 18, 19) have demonstrated that the 8-17-epoxy-12E-labdene-15,16-dial (2) from a myoga extract strongly suppressed the 12-O-tetradecanoylphorbol-13-acetate-induced superoxide generation in HL-60 cells, lipopolysaccharide/interferon--induced nitric oxide generation in RAW264.7 cells, and HL-60 cellinduced mutagenicity in AS52 cells. Despite this work, there have been few studies on the effects of a myoga extract on platelet aggregation and 5-lipoxygenase (5-LOX) affecting inflammatory responses.
We isolated in the current study a novel labdane type of diterpene from the flower buds of myoga that inhibited human platelet aggregation and human 5-LOX. We also determined its structure and compared its inhibitory activity with that of its related analogues including polygodial.
Materials and Methods
Materials and reagents. Fresh flower buds of myoga were purchased from a market in Takasaki City, Japan. 2, 3 and 4 were isolated as reported.
2) The fresh flower buds of myoga (500 g) were homogenized in ethyl acetate with a blender. The homogenate was allowed to stand for 3 h at room temperature. After filtration, the filtrate was concentrated under reduced pressure and then fractionated by flash chromatography in a silica gel FL-100DX column (Fuji Silysia Co.; 2 Â 40 cm) with ethyl acetate-benzene-chloroform (1:4:6) as the solvent. The most active fraction was separated by HPLC using 4% acetone in n-hexane as the mobile phase at a flow rate of 4.0 ml/min, to give 2 and 3 and 4. (E)-labda-8(17),12-diene-15,16-dial 5 and 8(17)-epoxy-15-hydroxy-12(E)-labden-16-al 6 were prepared from the rhizomes of ginger. Sliced ginger (500 g) was extracted with n-hexane for 24 h at room temperature. After filtration and evaporation, the residue was subjected to HPLC in a Develosil ODS-5 column (8 Â 250 mm) with methanol/H 2 O/acetic acid (80/20/0.1) as the mobile phase at a flow rate of 3 ml/min to give 5 and 6. 20) Polygodial 8 was prepared from the leaves of Polygonum hydropiper L. by the method Barnes and Loder. 21) Preparation of reduced miogadial 7. 2 was reduced as reported.
2) To an ice-cold solution of 2 (20 mg) in dry THF (3 ml), NaBH 4 (20 mg) was added, and the reaction mixture was stirred at 0 C for 1.5 h, before being poured into ice-cooled water. The mixture was then extracted with diethyl ether, and the diethyl ether solution was washed, dried and evaporated. The residue was separated by TLC to afford a colorless powder, which was confirmed by MS and NMR to be a diol compound corresponding to 2. The structure of this compound is shown in Fig. 1 .
Equipment. HPLC was performed with a Shimadzu LC-10AS instrument equipped with a Tosoh silica-60 column (7:8 Â 300 mm) and a UV detector (233 nm). UV spectra were recorded with a Shimadzu UV-160 spectrophotometer, optical rotation was measure with a Jasco P-1010 polarimeter, and IR spectra were recorded with a Jasco FTIR-420 spectrometer.
1 H-(400 MHz) and 13 C-(100 MHz) NMR spectra were respectively obtained with a Jeol EX-400 NMR spectrometer and a Bruker ARX-400 spectrometer in CDCl 3 , with tetramethylsilane used as the internal standard. MS spectra were recorded with a Jeol JMS 700 mass spectrometer. Extraction and isolation of 1. Fresh inflorescences of myoga (500 g) were sliced and homogenized in 1.5-liter of ethyl acetate with a blender. After soaking for 3 h at room temperature, the ethyl acetate extract was passed through filter paper (No. 2) under reduced pressure. This extraction procedure was conducted twice. The combined ethyl acetate extracts were dried on anhydrous Na 2 SO 4 and then concentrated in vacuo at 30 C to give an oily residue. The concentrate was successively divided into three fractions (A-C) by silica gel column chromatography in a Kieselgel 60 column (2 Â 20 cm), using 15% acetone in n-hexane as the solvent. All the fractions were concentrated and tested for their inhibition of platelet aggregation. Fraction B showed the strongest ability to inhibit platelet aggregation. This fraction was concentrated under reduced pressure at 30 C and then subjected to HPLC, using 4% acetone in n-hexane as the mobile phase at a flow rate of 4 ml/min. 2 and 1 were respectively eluted at retention times of 20.5 and 22.5 min. To purify compound 1, the HPLC procedure was conducted three times, resulting in a colorless oily compound (about 20 mg). The ethanol solution of 1 did not have any strong taste. Preparation of human platelets. 22) Venous blood was obtained from healthy donors by withdrawing into plastic syringes containing 1/10 final volume of 3.8% sodium citrate as an anticoagulant. Platelet-rich plasma was prepared by centrifuging the citrate-treated blood at 120 Â g for 10 min. Platelet-poor plasma was obtained by centrifuging the residue at 1100 Â g for 15 min. All procedures were performed at room temperature.
Platelet aggregation measurement and IC 50 determination. 22) Platelet aggregation was measured by turbidimetry with a dual-channel aggregometer (PA-20 Aggregation Analyzer; Kowa). Platelet-poor plasma was used as a control for 100% transmittance. In all experiments, 270 ml of platelet-rich plasma (250,000 platelets/ml) and 1 ml of the test compound in methanol were incubated at 37 C for 1 min while stirring. Aggregation was induced by adding 20 ml of an ADP solution (final concentration of 10 mM) or 20ml of arachidonic acid (AA) solution (final concentration of 0.5 mM). The IC 50 value was determined as the aggregation compared to that of the negative control (no added test compound). These experiments were carried out under experimental and ethical guidance for biohazard safety.
Assay of human 5-LOX inhibition. 23, 24) Briefly, the inhibitory effect of a test compound on human 5-LOX was measured by following the production of 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) from AA. The assay mixture (100 ml total volume) contained 0.1 M Tris-HCl (pH 8.0), 10 mM CaCl 2 , 10 mM ATP, 10 mg of sonicated phosphatidylcholine, the test sample in DMSO, and 100 mg of 5-LOX (Cayman Chemical). The mixture was warmed to 30 C for 5 min, after which the reaction was initiated by adding 50 mmol AA. After 10 min at 30 C, the reaction was terminated by adding 0.3 ml of cold (À20 C) methanol containing 0.2 mmol of 13-hydroxylinoleic acid (Cayman Chemical) as an internal standard and 1 ml of 1 M acetic acid. Following centrifugation at 11,000 rpm for 10 min, the supernatant was analyzed by HPLC.
Analytical procedure. The level of 5-HETE derived from AA was measured by HPLC with a Shimadzu LC-10AT equipped with an autosampler and a Capcellpak C18 column (4:6 Â 150 mm; Shiseido), using methanol/water/acetic acid (80:20:0.01) as the solvent and detecting at 233 nm. The control was performed in triplicate. The IC 50 value was determined as the concentration of the compound that gave 50% inhibition of the production of 5-HETE compared with the negative control (no added test compound).
Results and Discussion

Structure of 1
The results of 13 C-NMR and 1 H-NMR of 1 are shown in Table 1 . Based on the EI-MS and HR-MS measure- (15, 16, 17-H) , two alkene (12-H, 13-C), and two quaternary carbons (4, 10-C). To satisfy the degree of unsaturation, 1 should have two rings in the structure.
As shown in Table 1 , there are some similarities in the NMR data between 1 and 2.
2) The 1 H-1 H COSY and HMQC experiments on 1 show the presence of four partial structures (shown as bold lines in Fig. 2 ; 1-C-3-C, 7-C-17-C, 11-C-12-C, and 14-C-15-C). In the HMBC experiment, long-range correlation was observed between the following protons and carbons of 1: 5-H and 1-C, 7-C, 10-C; 9-H and 7-C; 12-H and 16-C; 16-H and 13-C; 17-H and 8-C; 18-H and 3-C; and 20-H and 1-C. In addition, the EI-MS spectrum of 1 showed the characteristic fragment ion peak (m=z 137) of a labdane type of diterpene. 25) These data confirm that the planar structure of 1 was labd-12-ene-15,16,17-trial.
In the NOESY experiment for 1, NOE correlation was observed between the 12-olefin proton and the 16-aldehyde proton. The data indicate that the double bond (12-C to 13-C) had an E geometry. [26] [27] [28] Furthermore, NOE correlation was observed between the 20-methyl proton and 17-aldehyde proton, and between 5-H and both 8-H and 9-H. The orientations of the 8-aldehyde group and 9-H were confirmed to be -equatorial and -axial, respectively. [25] [26] [27] Thus, by examining the molecular model generated from the foregoing data, the relative structure of 1 was determined for the first time to be 12(E)-labdene-15,16,(8)17-trial, which we have named miogatrial 1. Unsaturated diterpenes with three aldehyde groups are rare in natural products. 29) One example, halimedatrial, has been isolated from the tropical marine algae, Halimeda, as an effective feeding deterrent to herbivorous fishes. 30) It was therefore assumed that 1 would possess some biological activities, even though it did not have the hot taste characteristic of myoga.
Inhibition of human platelet aggregation
As shown in Table 2 , we examined the ability of the diterpene compounds isolated from myoga to inhibit the AA-and ADP-induced aggregation of human platelets. Aspirin and indomethacin were used as positive controls because they are known inhibitors of platelet aggregation. 31) We found that 1 and 2 inhibited the ADPinduced platelet activation with IC 50 values of 3.5 and 3.0 mM, respectively. The IC 50 values of 3 and 4 were 268 and 287 mM, respectively. Furthermore, 5 inhibited human platelet aggregation with an IC 50 value of 3.2 mM. We also found for the first time that polygodial 8, a pungent component of Polygonum hydropiper L., strongly inhibited human platelet aggregation (IC 50 ¼ 4:9 mM). In contrast, 6 and 7 did not inhibit platelet aggregation. In respect of the AA-induced platelet aggregation, 1 and 2 had IC 50 values of 11.9 and 10.7 mM, respectively, being approximately 25% as potent as indomethacin. Interestingly, 1 and 2 were significantly more potent than aspirin (IC 50 ¼ 41:2 mM), while 3, 4 and 7 did not inhibit AA-induced platelet aggregation. Collectively, these results suggest that a 3-formyl-3-butenal structure was important for the ability of these compounds to inhibit platelet aggregation. AA plays an important role in platelet aggregation, and is released upon the activation of platelets due to the breakdown of membrane phospholipids by phospholipase A 2 .
32) Liberated AA is rapidly converted to prostaglandin and then to thromboxane A 2 by cyclooxygenase and thromboxane synthase. Our data indicate that 1 and 2 were approximately four-fold more potent than aspirin at inhibiting AA-induced platelet aggregation. Compound 2 has also been isolated from the rhizomes of ''Kintoki'' ginger during a series of studies on crude Chinese drugs by Kano et al. 33) Similar to our results here, Kawakishi et al. have demonstrated 2 to be a potent inhibitor of ADP-induced platelet aggregation. 20) They have also shown that 2 did not inhibit prostaglandin biosynthesis by rabbit renal microsomes. They proposed that this was due to inhibition of the ADP receptor on platelets in a manner similar to o-phthalaldehyde, which inhibits ADP from binding to platelets by reacting with the thiol and amino groups. Whether the other potent inhibitor of platelet aggregation, 1, affects prostaglandin biosynthesis remains to be determined.
Inhibition of human 5-LOX
We next examined the effects of 1, 2 and its analogues, and 8 (the pungent component of Polygonum hydropiper L.) on 5-LOX. Nordihydroguaiaretic acid and AA861 were used as positive controls for the inhibition of 5-LOX. 20, 34) As shown in Table 3 , 1 and 2 inhibited 5-LOX with IC 50 values of 7.5 and 4.0 mM, respectively. The IC 50 values of 5 and 6 were 18.9 mM and >100 mM, respectively. 8, a sesquiterpene dialdehyde, inhibited 5-LOX with an IC 50 value of 8.6 mM, while 3, 4 and 7 did not have inhibitory activity. Of the tested compounds, 1, 2, 5, and 8 had a 3-formyl-3-butenal structure and were all relatively potent inhibitors of 5-LOX. Although the IC 50 values of 1 and 2 differ by approximately two-fold, it appears that an aldehyde group is equivalent to an epoxy group at 17-C for the inhibition of 5-LOX. However, 6, which has an epoxy group at 17-C, did not inhibit 5-LOX. In addition, 3 and 4, which do not have a 3-formyl-3-butenal structure, were also unable to inhibit 5-LOX. It thus appears that, amongst the tested compounds, a 3-formyl-3-butenal structure was important for the ability to inhibit human 5-LOX.
5-LOX is the first enzyme in the leukotriene biosynthesis pathway. It catalyzes the oxygenation of AA to form 5-hydroperoxyeicosatetraenoic acid. Since leukotrienes play an important role in inflammation and anaphylaxis, many studies have attempted to isolate inhibitors of 5-LOX from natural products or foods. [35] [36] [37] [38] For example, da Cunha et al. 39) have demonstrated that the sesquiterpene, polygodial, which has a 3-formyl-3-butenal structure, possessed interesting anti-inflammatory and anti-allergic properties in rats and mice. Since 8 was a potent inhibitor of 5-LOX, we suspect that 1 and 2 would have anti-inflammatory and anti-allergic effects in vivo. Indeed, the flower buds of myoga and its rhizomes have been employed in Japan as a folk medicine to treat rheumatism. 15) Thus, our finding that the compounds from myoga inhibited 5-LOX supports the use of myoga as a natural anti-inflammatory agent.
In conclusion, we isolated and characterized the novel diterpene trialdehyde, 12(E)-labdene-15,16,(8)17-trial (miogatrial), from myoga. This compound had equally inhibitory activities against the aggregation of human platelets and the enzymatic activity of human 5-LOX. Based on the effects of related compounds, it appears that a 3-formyl-3-butenal structure was essential for the potent inhibition of both human platelet aggregation and human 5-LOX activity. Though further studies are necessary to determine the molecular mechanism and the in vivo effects of both 1 and 2, our results suggest that the flower buds of myoga contained compounds that could potently inhibit platelet aggregation and inflammatory responses and that therefore may be useful for the treatment of chronic inflammation. 
